EYLEA HD

targets

all catalysts(5)

News(10)

• Kodiak skyrockets on positive study data for 2 eye drugs
  The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
  biopharma_dive · 4h ago
• Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
  Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
  endpoints · 5h ago
• Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
  Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
  biospace · 5h ago
• STAT+: AbbVie wins FDA nod for Parkinson’s pill
  The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.
  stat · 6h ago
• Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
  Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.
  fiercebiotech · 12h ago
• Merck sees pivotal victory for $3B eye disease prospect
  Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
  fiercebiotech · 4d ago
• Regeneron to challenge Ipsen as FDA clears bone disease drug
  Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
  biopharma_dive · 1mo ago
• EyePoint’s bid to compete with Eylea falls flat
  EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…
  endpoints · 1mo ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 1mo ago
• EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
  EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
  biospace · 1mo ago